{"url_path":"/sec/tcrt/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1107421/0001193125-26-227272-index.html","accession_number":"0001193125-26-227272","cik":"0001107421","ticker":"TCRT","issuer_name":"Alaunos Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1107421/0001193125-26-227272-index.html","primary_entity_key":"0001107421","primary_entity_name":"Alaunos Therapeutics, Inc."},"word_count":415,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\n \n\nExhibit\n\nNumber\n\nDescription\n\n3.1\n\n[Second Amended and Restated Certificate of Incorporation of Alaunos Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, SEC File No. 001-33038, filed February 1, 2024).](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001107421/000119380524000111/e619211_8k-at.htm)\n\n3.2\n\n[Certificate of Designation of Series A-1 Convertible Preferred Stock of Alaunos Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on April 14, 2025).](https://www.sec.gov/Archives/edgar/data/1107421/000095017025053523/tcrt-ex3_1.htm)\n\n \n\n \n\n3.3\n\n[Certificate of Designation of Series A-2 Convertible Preferred Stock of Alaunos Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on June 26, 2025).](https://www.sec.gov/Archives/edgar/data/1107421/000095017025090201/tcrt-ex3_1.htm)\n\n \n\n \n\n3.4\n\n[Amended and Restated Bylaws of the Registrant, dated as of September 21, 2020 (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, SEC File No. 001-33038, filed September 22, 2020).](https://www.sec.gov/Archives/edgar/data/1107421/000119312520250711/d42031dex31.htm)\n\n \n\n \n\n31.1+\n\n[Certification of Principal Executive Officer and Principal Financial Officer pursuant to Exchange Act Rule 13a-14(a) or 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](tcrt-ex31_1.htm)\n\n32.1++\n\n[Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](tcrt-ex32_1.htm)\n\n101.INS+\n\nInline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).\n\n101.SCH+\n\nInline XBRL Taxonomy Extension Schema Document\n\n104+\n\nCover Page Interactive Data File—the cover page interactive data is embedded within the Inline XBRL document or included within the Exhibit 101 attachments\n\n+\n\nFiled herewith.\n\n++\n\nThis certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.\n\n \n\n \n\n19\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\nALAUNOS THERAPEUTICS, INC.\n\nBy:\n\n/s/ Holger Weis\n\nHolger Weis\n\nChief Executive Officer\n\n(On Behalf of the Registrant and as Principal Executive Officer and Principal Financial Officer)\n\nDated: May 15, 2026\n\n \n\nBy:\n\n/s/ Ferdinand Groenewald\n\nFerdinand Groenewald\n\nVice President, Finance\n\n(Principal Accounting Officer)\n\nDated: May 15, 2026\n\n \n\n \n\n \n\n20"}